# A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Source: https://onco.cc/trials/nct05485948/  
OnCo record `nct05485948` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ropeginterferon alfa-2b in myeloproliferative neoplasms, run by PharmaEssentia, active and no longer recruiting.

## Summary

A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU is a phase 2 interventional study registered as NCT05485948 by PharmaEssentia, with 49 participants enrolled, started 2021-10-08 and due to reach its primary completion in 2022-09-07. Interventions recorded: Ropeginterferon alfa-2b.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05485948
- Phase: 2
- Setting: A Phase II Single-Arm Multicenter Study to Access Efficacy and Safety of P1101 in Chinese Polycythemia Vera Patients Who Are Intolerant or Resistance to Hydroxyurea
- Sponsor: PharmaEssentia
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT05485948: https://clinicaltrials.gov/study/NCT05485948

## Connected records

- cancers: [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [Ropeginterferon alfa-2b](https://onco.cc/drugs/ropeginterferon-alfa-2b/)
- companies: [PharmaEssentia](https://onco.cc/companies/pharmaessentia/)

---
JSON: https://onco.cc/api/v1/entities/nct05485948.json